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Background: Reducing the severity of respiratory symptoms is a key goal in the treatment of chronic obstructive
pulmonary disease (COPD). We evaluated the effect of aclidinium bromide 400 μg twice daily (BID) on respiratory
symptoms, assessed using the Evaluating Respiratory Symptoms in COPD (E-RS™: COPD) scale (formerly EXACT-RS).
Methods: Data were pooled from the aclidinium 400 μg BID and placebo arms of two 24-week, double-blind,
randomized Phase III studies evaluating aclidinium monotherapy (ATTAIN) or combination therapy (AUGMENT
COPD I) in patients with moderate to severe airflow obstruction. Patients were stratified by Global initiative for
chronic Obstructive Lung Disease (GOLD) Groups A–D. Change from baseline in E-RS scores, proportion of
responders (patients achieving pre-defined improvements in E-RS scores), and net benefit (patients who improved
minus patients who worsened) were analyzed.
Results: Of 1210 patients, 1167 had data available for GOLD classification. Mean (standard deviation) age was 63.2 (8.6)
years, 60.7 % were male, and mean post-bronchodilator forced expiratory volume in 1 s was 54.4 % predicted. Compared
with placebo, aclidinium 400 μg BID significantly improved RS-Total (2.38 units vs 0.79 units, p < 0.001) and domain scores
(all p< 0.001) at Week 24, and doubled the likelihood of being an RS-Total score responder (p < 0.05), irrespective of
GOLD group. The net benefit for RS-Total (Overall: 56.9 % vs 19.4 %; A + C: 65.7 % vs 6.3 %; B + D: 56.0 % vs 20.8 %, for
aclidinium 400 μg BID and placebo respectively; all p < 0.05) and domain scores (all p < 0.05) was significantly greater with
aclidinium compared with placebo, in both GOLD Groups A + C and B +D.
Conclusions: Aclidinium 400 μg BID significantly improved respiratory symptoms regardless of the patients’ level of
symptoms at baseline. Net treatment benefit was similar in patients with low or high levels of symptoms.
Trial registration: ATTAIN (ClinicalTrials.gov identifier: NCT01001494) and AUGMENT COPD I (ClinicalTrials.gov identifier:
NCT01437397).
Keywords: Cohort, Retrospective, Prospective, Exacerbation risk, Nighttime symptoms, Morning symptoms* Correspondence: pjones@sgul.ac.uk
1St George’s, University of London, London, UK
Full list of author information is available at the end of the article
© 2016 Jones et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Jones et al. Respiratory Research  (2016) 17:61 Page 2 of 11Background
Respiratory symptoms, including breathlessness, chronic
cough, and sputum production, are characteristic features
of chronic obstructive pulmonary disease (COPD) [1].
These are generally progressive and become increasingly
debilitating as the disease worsens. The presence of
respiratory symptoms is associated with poor health
outcomes, including reduced health status and an in-
creased exacerbation risk [2–4]. Although the primary out-
comes in clinical trials of bronchodilators are typically
post-bronchodilator forced expiratory volume in 1 s (FEV1)
endpoints, symptomatic outcomes may better reflect the
impact of treatment on patients’ daily lives. It is therefore
important to have validated, reliable tools to assess the
effect of treatment on symptoms in clinical trials.
Whilst other patient-reported outcomes, such as the
St George’s Respiratory Questionnaire (SGRQ; a meas-
ure of health status) [5] and the transition dyspnea index
(TDI; a measure of the impact of breathlessness on daily
activities) [6], are commonly assessed in COPD clinical
trials, until recently there has been no standardized
method for quantifying daily respiratory symptoms. The
EXAcerbations of Chronic obstructive pulmonary dis-
ease Tool (EXACT) is a daily diary which is completed
by the patient in the evening, with a recall period of
‘today’ to assess acute exacerbations of COPD and
chronic bronchitis [7–9]. Recently, the Evaluating
Respiratory Symptoms in COPD (E-RS™1: COPD)
tool, a derivative of the EXACT and previously re-
ferred to as EXACT-RS, was developed to meet the
need for a standardized respiratory symptom diary.
The E-RS uses the 11 respiratory symptom items
from the 14-item EXACT and assesses both overall
daily respiratory COPD symptoms (RS-Total score)
and specific respiratory symptoms using three sub-
scales (RS-Breathlessness, RS-Cough & Sputum and
RS-Chest Symptoms) [10, 11].
Aclidinium bromide 400 μg twice daily (BID) is a
long-acting muscarinic antagonist approved as a main-
tenance bronchodilator treatment in patients with
COPD. In this post-hoc analysis, we pool data from the
aclidinium 400 μg and placebo arms of two 24-week,
double-blind, randomized Phase III studies of aclidi-
nium monotherapy (ATTAIN) or combination ther-
apy (AUGMENT COPD I) [12, 13] to evaluate the
effect of aclidinium on respiratory symptoms,
assessed using the E-RS. Patients were stratified ac-
cording to Global initiative for chronic Obstructive
Lung Disease (GOLD) Groups A–D in order to in-
vestigate how RS-Total scores and the effect of acli-
dinium relate to these patient groups.
Additionally, we investigated the relationship be-
tween E-RS scores and other clinical measures at
baseline and over time.Methods
Study design
ATTAIN (ClinicalTrials.gov identifier: NCT01001494)
and AUGMENT COPD I (ClinicalTrials.gov identifier:
NCT01437397) were multi-national, randomized, double-
blind, placebo-controlled Phase III studies evaluating acli-
dinium monotherapy (ATTAIN) [12] or combination
therapy (AUGMENT COPD I) [13]. In both studies, fol-
lowing screening and a 2–3-week run-in period, patients
were randomized to 24 weeks’ treatment with: aclidinium
200 μg BID, aclidinium 400 μg BID (metered dose; equiva-
lent to aclidinium 322 μg delivered dose) or placebo BID
in ATTAIN (1:1:1); and aclidinium bromide/formoterol
fumarate (AB/FF) 400/12 μg BID, AB/FF 400/6 μg BID,
aclidinium 400 μg BID, formoterol 12 μg BID or placebo
BID (1:1:1:1:1) in AUGMENT COPD I. The ACLIFORM
COPD study (ClinicalTrials.gov identifier: NCT01462942),
which was of similar design to AUGMENT COPD I, was
not included in this pooled analysis due to a large and un-
explained placebo effect in health status assessments [14];
given the significant correlation between health status and
the E-RS [11], it is not clear how the placebo effect
impacted E-RS assessments in this study, therefore a deci-
sion was made prospectively not to include these data in
this analysis.
All treatments were administered via the GenuairTM/
Pressair®2 inhaler. Inhaled albuterol/salbutamol (108/
100 μg/puff ) was permitted as relief medication, as long
as it was discontinued 6 h prior to study visits in both
studies. Details of other permitted concomitant and
restricted medications have been reported elsewhere
[12, 13].
Both studies were conducted in accordance with the
Declaration of Helsinki, International Conference on
Harmonization/Good Clinical Practice Guidelines and
local regulations. The study protocols were approved
by Institutional Review Boards/Independent Ethics
Committees as required by each country and all pa-
tients gave written informed consent.Study populations
Detailed inclusion/exclusion criteria for each study have
been reported previously [12, 13]. Briefly, both studies
enrolled male and female patients (≥40 years old) with a
diagnosis of stable COPD and moderate to severe airflow
obstruction (FEV1 ≥30 % and <80 % of the predicted
value and FEV1/forced vital capacity ratio <70 %) [1]
who were current or former smokers with a smoking
history of ≥10 pack-years. A history of respiratory symp-
toms was not a specific inclusion criterion in either of
the studies.
Exclusion criteria included any respiratory tract in-
fection or COPD exacerbation within 6 weeks prior
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hospitalization), any clinically relevant respiratory or
cardiovascular conditions, including a history or
current diagnosis of asthma and a history of hyper-
sensitivity to inhaled anticholinergic agents or other
inhaled medications.Assessments
Daily COPD respiratory symptoms
Every evening, patients completed the EXACT diary, from
which daily COPD symptom scores were derived using
the E-RS scoring algorithms [10, 11]. The RS-Total score
is the sum of 11 items that relate specifically to respiratory
symptoms (score range, 0–40), with higher scores indica-
ting more severe symptoms. The RS-Breathlessness
domain is the sum of five items related to breathlessness
(score range, 0–17); the RS-Cough & Sputum domain
score is the sum of three items that relate to cough and
sputum symptoms (score range, 0–11); and the RS-Chest
Symptoms domain score is the sum of three items related
to chest congestion/discomfort (score range, 0–12).
RS-Total and domain scores were assessed at baseline and
over the 24-week study duration. Responder definitions
for the E-RS have been proposed and are shown in Table 1.
These responder definitions for symptomatic improve-
ment were based on results from three randomized con-
trolled trials in which responder definitions were defined
using criterion- and distribution-based methods [11]. For
this analysis, responder status was assessed using data at
baseline (averaged over the week before randomization)
and at the end of the study (averaged over the last week of
the study).Table 1 Clinical outcome measure responder definitions
Outcome Res
Daily respiratory symptomsa
RS-Total score ≥2
RS-Breathlessness domain score ≥1
RS-Cough & Sputum domain score ≥0
RS-Chest Symptoms domain score ≥0
Health status
SGRQ total score ≥4
Dyspnea
TDI focal score ≥1
Lung function
Trough FEV1 (spirometry) ≥1
aHigher scores indicate more severe symptoms
bPatients with a decrease from baseline that exceeded the pre-defined value were c
baseline that exceeded the pre-defined value were considered to have a worsening
pre-defined value were considered to have no change
FEV1, forced expiratory volume in 1 s; SGRQ, St George’s Respiratory Questionnaire;Other clinical outcomes
FEV1 was measured before the morning dose on Day 1
(baseline) and at each study visit (trough FEV1). Dyspnea
was assessed at baseline using the baseline dyspnea
index (BDI) and changes in dyspnea were assessed with
the TDI [6]. Health status was assessed using the SGRQ
[5]. Responders for each outcome were defined as pa-
tients who achieved a clinically meaningful improvement
from baseline (Table 1).Endpoints
The endpoints examined in this predefined analysis of
data from the ATTAIN and AUGMENT COPD I tri-
als [12, 13], were changes from baseline in RS-Total
and domain scores at Week 24 and the percentage of
RS-Total and domain score responders at Week 24.
In addition, a net treatment benefit was calculated as
the proportion of patients who had an improvement
minus the proportion of patients who had a worsen-
ing. Response and worsening were determined using
published threshold estimates for meaningful change
(Table 1). Patients with a change from baseline in ei-
ther direction that did not exceed the responder
threshold were considered to have ‘no change’.
The relationship between E-RS responder status at
Week 24 and responder status for other clinical outcomes
was also evaluated. In addition, baseline E-RS scores were
correlated with baseline measures of health status (SGRQ
total score), dyspnea (BDI focal score), relief-medication
use and airflow obstruction (post-bronchodilator FEV1).
Safety and tolerability outcomes have been reported
for each of the studies previously [12, 13].ponder definitionb Reference
-unit decrease from baseline [11]
-unit decrease from baseline
.7-unit decrease from baseline
.7-unit decrease from baseline
-unit decrease from baseline [19]
-unit increase from baseline [20]
00 mL increase from baseline [21]
onsidered to have an improvement (responders). Patients with an increase from
. Patients with a change from baseline in either direction that did not reach the
TDI, transition dyspnea index
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These post-hoc analyses were conducted using data from pa-
tients randomized to placebo or aclidinium 400 μg BID (the
dose licensed for use in patients with COPD). Data from pa-
tients in the intent-to-treat (ITT) population (all random-
ized patients who took at least one dose of double-blind
treatment and had a baseline and at least one post-baseline
FEV1 assessment) who also had baseline SGRQ and E-RS
scores were evaluated. All other treatment arms and time
points were excluded from analysis. The primary analysis
was performed on patients randomized to treatment, but a
secondary analysis tested the effect of treatment versus pla-
cebo in patients stratified into GOLD Groups A–D based
on airflow obstruction, exacerbation risk, and SGRQ total
score. GOLD recommends use of the COPD Assessment
Test (CAT) score, or the modified Medical Research Coun-
cil (mMRC) dyspnea grade, but as neither CAT score nor
mMRC grades were assessed in ATTAIN or AUGMENT,
the SGRQ total score was used as a surrogate to stratify pa-
tients [15]. An SGRQ total score of ≥25 was used, as this
corresponds with a CAT score of ≥10 [15]. For efficacy ana-
lyses, low symptom patients in GOLD Groups A and C
were pooled (A +C); similarly, the higher-symptom patients
in Groups B and D were pooled (B +D).
Baseline data are reported as mean (standard deviation
[SD]) or percentage. Variation in baseline E-RS scores
between individual (A, B, C, D) and pooled (A + C and
B + D) GOLD groups was analyzed using analysis of co-
variance (ANCOVA) models, with E-RS score as the
dependent variable and GOLD group, study, sex, and
tobacco use as factors and age as a covariate. A mini-
mum of four of seven days of diary data were required
for computation of baseline scores in both trials.
Changes from baseline in RS-Total and domain scores at
Week 24 were analyzed using a mixed model for repeated
measures, adjusted for baseline, treatment, visit, sex, age,
smoking status, and treatment-by-visit interaction. These
are reported as least squares (LS) means (standard error).
The proportion of RS-Total and domain, SGRQ, TDI, and
trough FEV1 responders was analyzed using a logistic
random-effects model and data are reported as odds ratio
(OR; 95 % confidence intervals).
The relationship between RS-Total and domain score
responders and trough FEV1, SGRQ, or TDI responders
was assessed in the total patient population using a chi-
squared test. Pearson’s correlation co-efficient (r) was
used to assess the correlation between baseline RS-Total
score and SGRQ total score, BDI, relief-medication use,
and % predicted post-bronchodilator FEV1 at baseline.
Results
Patient population
Patient demographic and baseline clinical characteristics
for ATTAIN and AUGMENT COPD I are shown inTable 2. Overall, there were 1210 patients in the pooled
ITT population. Of these, 1161 patients had baseline
E-RS and SGRQ data available and were included in
these post-hoc analyses (Additional file 1: Table S1).
Using baseline SGRQ data, patients were categorized
into GOLD groups as follows: GOLD Group A,
n = 96 patients; GOLD Group B, n = 568; GOLD
Group C, n = 42; and GOLD Group D, n = 461.
Overall, the mean (SD) age was 63.2 (8.6) years,
60.6 % of patients were male, and mean (SD) post-
bronchodilator FEV1 was 1.6 (0.5) L.Baseline E-RS scores
Mean E-RS scores at baseline are shown in Table 3. At
baseline, overall mean (SD) RS-Total score was 12.6 ±
6.6 (range 0–34), but there was a significant difference
in RS-Total and domain scores between GOLD groups
(ANCOVA, p < 0.001 for total score and all domains).
The RS-Total and domain scores were higher in Groups
B and D compared with Groups A and C (all p < 0.001).
In addition, RS-Total and RS-Breathlessness scores were
higher in Group D (higher symptom higher risk) com-
pared with Group B (higher symptom lower risk) (both
p < 0.001). Baseline RS-Total and domain scores were
balanced between treatment arms in each pooled GOLD
group (A + C and B + D), with the exception of
RS-Cough & Sputum domain scores in patients in
GOLD Group A + C, which were significantly greater in
the aclidinium group compared with placebo (p < 0.05;
Additional file 1: Table S2). The distribution of baseline
E-RS scores by pooled GOLD group is shown in Fig. 1,
and analyzing the data by individual GOLD group yields
similar results (Additional file 1: Figure S1).Efficacy analyses
Changes from baseline in RS-Total and domain scores at
Week 24 are shown in Fig. 2. After 24 weeks, in the
overall patient population, the improvement from base-
line in RS-Total score was significantly greater with
aclidinium compared with placebo (p < 0.001; Fig. 2a);
2.38 units with aclidinium versus 0.79 units with
placebo. For each of the E-RS domains, improvements
from baseline in E-RS score in the overall population
were also significantly greater with aclidinium (all
p < 0.001; Fig. 2c, e, g). The magnitude of the treatment
differences with aclidinium versus placebo for RS-Total
score and each of the E-RS domains were numerically
similar, irrespective of GOLD group (Fig. 2a, c, e, g).
Overall, patients receiving aclidinium were significantly
more likely to be an RS-Total score responder compared
with patients receiving placebo (OR 2.2, p < 0.001; Fig. 2b).
Similarly, patients in the aclidinium group were approxi-
mately twice as likely to be responders in the three
Table 2 Baseline demographic and clinical characteristics by treatment, study and overall
ATTAIN AUGMENT COPD Pooled analysis sample
Characteristic Aclidinium 400 μg
(n = 269)a
Placebo
(n = 273)a
Aclidinium 400 μg
(n = 337)a
Placebo
(n = 331)a
Aclidinium 400 μg
(n = 583)b
Placebo
(n = 578)b
All patients
(n = 1161)b
Age, years, mean (SD) 62.9 (8.4) 62.0 (8.0) 64.4 (8.7) 63.5 (8.9) 63.7 (8.6) 62.8 (8.5) 63.2 (8.6)
Male, n (%) 182 (67.7) 189 (69.2) 188 (55.8) 175 (52.9) 356 (61.1) 347 (60.0) 703 (60.6)
Caucasian, n (%) 257 (95.5) 260 (95.2) 314 (93.2) 316 (95.5) 548 (94.0) 552 (95.5) 1100 (94.7)
BMI, kg/m2, mean (SD) 27.0 (4.8) 26.6 (5.2) 27.5 (5.3) 27.7 (5.6) 27.3 (5.1) 27.2 (5.5) 27.2 (5.3)
Current smoker, n (%) 148 (55.0) 144 (52.8) 171 (50.7) 169 (51.1) 303 (52.0) 300 (51.9) 603 (51.9)
Smoking history, pack-years,
mean (SD)
41.7 (21.1) 38.9 (18.3) 52.0 (26.1) 53.4 (28.5) 47.1 (23.4) 47.1 (25.8) 47.1 (24.6)
Post-bronchodilator FEV1, L,
mean (SD)c
1.6 (0.5) 1.6 (0.5) 1.5 (0.5) 1.6 (0.5) 1.6 (0.5) 1.6 (0.5) 1.6 (0.5)
Post-bronchodilator FEV1,
% predicted, mean (SD)c
56.2 (12.2) 56.6 (12.8) 53.0 (13.3) 52.6 (13.3) 54.5 (12.9) 54.2 (13.3) 54.4 (13.1)
% bronchial reversibility (SD) 11.3 (12.9) 12.3 (15.7) 19.1 (16.5) 18.4 (15.2) 15.7 (15.6) 15.7 (15.7) 15.7 (15.6)
Number of exacerbations in previous
year, mean (SD)
0.5 (0.7) 0.4 (0.9) 0.3 (0.8) 0.3 (0.6) 0.4 (0.8) 0.3 (0.7) 0.4 (0.8)
aPatients from the ITT population
bPatients from the pooled subpopulation: ITT population (N = 1210) with data available for GOLD classification (43 patients were excluded due to missing GOLD
data and a further 6 patients due to missing baseline E-RS data)
cAt screening visit
BMI, body mass index; COPD, chronic obstructive pulmonary disease; E-RS, Evaluating Respiratory Symptoms; FEV1, forced expiratory volume in 1 s; GOLD, Global
initiative for chronic Obstructive Lung Disease; ITT, intent-to-treat; SD standard deviation
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all p < 0.001; Fig. 2d, f, h).
When assessed according to GOLD group, with the
exception of the RS-Breathlessness domain score in pa-
tients in GOLD Group A + C (OR 1.6, p > 0.05; Fig. 2d),
the likelihood of achieving the pre-defined improvement
from baseline in RS-Total and domain scores was also
significantly greater with aclidinium compared with pla-
cebo in GOLD Group A + C and GOLD Group B + D
(OR 1.7–3.6, all p < 0.05; Fig. 2b, d, f, h).
The net benefit in RS-Total score was significantly
higher in patients treated with aclidinium than in
those receiving placebo. This was seen in the whole
treatment population and in patients classified as
GOLD Group A + C and B + D (all p < 0.01; Fig. 3a–
c). A similar pattern was observed for the E-RS do-
mains (all p < 0.05; Fig. 4a–c).
Association between E-RS responder status and other
clinical outcomes
There were significant associations between RS-Total
score responder status at Week 24 and responder
status for SGRQ total score, TDI focal score and
trough FEV1 (all p ≤ 0.002; Additional file 1: Figure
S2a). The strongest association was observed be-
tween responder status for RS-Total score and
SGRQ total score (χ2 = 118.9, p < 0.001).
There was also a significant relationship between re-
sponder status for each E-RS domain and responder sta-
tus for the SGRQ total and TDI focal scores (all p < 0.05;Additional file 1: Figure S2b–d). A significant association
was seen between E-RS Breathlessness domain
responders and trough FEV1 responders (p = 0.001;
Additional file 1: Figure S2b), but no association was
found between RS-Chest Symptoms and RS-Cough &
Sputum responders and trough FEV1 responders
(Additional file 1: Figure S2c–d).
Correlation between E-RS scores and other clinical
outcomes
Baseline RS-Total and domain scores were significantly
correlated with baseline SGRQ total score, BDI focal
score, relief-medication use and FEV1 (all p < 0.05;
Additional file 1: Table S3).
Discussion
In this pooled analysis, after 6 months of treatment, acli-
dinium 400 μg BID significantly improved RS-Total and
domain scores compared with placebo and increased the
proportion of patients who achieved pre-defined im-
provements from baseline in E-RS scores. Pooling data
from two studies made available sufficient data for sub-
analysis by GOLD group, which demonstrated that acli-
dinium can improve respiratory symptoms in patients
with both low symptoms (GOLD Group A + C) or high
symptoms (GOLD Group B + D).
Symptoms are usually assessed in clinical trials by ask-
ing patients to recall their symptoms over a specified
period (e.g. since the last visit, past month, previous
week), but periodic assessment may be subject to recall
Table 3 Baseline E-RS scores, overall and by GOLD group
RS-Totala RS-Breathlessnessb RS-Cough & Sputumc RS-Chest Symptomsd
mean (SD) mean (SD) mean (SD) mean (SD)
All patients
Placebo (n = 578) 12.4 (6.5) 6.3 (3.6) 3.4 (1.9) 2.7 (2.0)
Aclidinium 400 μg BID (n = 583) 12.7 (6.8) 6.4 (3.7) 3.5 (1.9) 2.9 (2.1)
Total (n = 1161) 12.6 (6.6) 6.3 (3.6) 3.4 (1.9) 2.8 (2.0)
GOLD Group A
Placebo (n = 52) 4.6 (3.2) 2.0 (1.7) 1.6 (1.3) 0.9 (1.2)
Aclidinium 400 μg BID (n = 42) 6.0 (5.2) 2.3 (2.7) 2.3 (1.8) 1.4 (1.7)
Total (n = 94) 5.2 (4.3) 2.1 (2.2) 2.0 (1.6) 1.1 (1.5)
GOLD Group B
Placebo (n = 270) 13.1 (5.9) 6.5 (3.2) 3.6 (1.8) 3.0 (1.8)
Aclidinium 400 μg BID (n = 296) 13.1 (6.5) 6.4 (3.5) 3.6 (1.9) 3.1 (2.0)
Total (n = 566) 13.1 (6.2) 6.4 (3.3) 3.6 (1.8) 3.1 (1.9)
GOLD Group C
Placebo (n = 20) 6.5 (4.4) 3.0 (2.1) 2.0 (1.6) 1.5 (1.5)
Aclidinium 400 μg BID (n = 22) 6.0 (3.4) 2.3 (1.7) 2.4 (1.5) 1.3 (1.2)
Total (n = 42) 6.2 (3.9) 2.6 (1.9) 2.2 (1.6) 1.4 (1.4)
GOLD Group D
Placebo (n = 236) 13.9 (6.4) 7.3 (3.5) 3.6 (1.8) 2.9 (2.0)
Aclidinium 400 μg BID (n = 223) 14.2 (6.5) 7.5 (3.4) 3.6 (2.0) 3.2 (2.1)
Total (n = 459) 14.0 (6.5) 7.4 (3.5) 3.6 (1.9) 3.0 (2.1)
n = patients with available data
aRS-Total score ranged from 0 to 40
bRS-Breathlessness domain score ranged from 0 to 17
cRS-Cough & Sputum domain score ranged from 0 to 11
dRS-Chest Symptoms domain score ranged from 0 to 12
Higher scores indicate more severe symptoms
RS-Total and domain scores were higher in GOLD Groups B and D compared with Groups A and C (all p < 0.001; ANCOVA). RS-Total and RS-Breathlessness scores
were higher in GOLD Group D compared with Group B (both p < 0.001; ANCOVA)
ANCOVA, analysis of covariance; BID, twice daily; E-RS, Evaluating Respiratory Symptoms; GOLD, Global initiative for chronic Obstructive Lung Disease; SD, standard deviation
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symptoms that they experienced in the most recent past.
The E-RS was designed to meet the need for a daily
respiratory symptoms diary and, whilst its validity and
reliability has been demonstrated [10, 11], this is the first
test of its ability to capture treatment effects.
Criteria for defining RS-Total and domain score re-
sponders have been proposed [11] and in the overall pa-
tient population, and in patients in GOLD Group B + D,
improvements from baseline in RS-Total and domain
scores with aclidinium met or exceeded the thresholds
for defining responders. Aclidinium improved daily
respiratory symptoms in all groups irrespective of base-
line symptom severity. However, although the largest
changes were seen in those with more severe symptoms
at baseline, it should be noted that the number of pa-
tients in the low symptom group was relatively small.
After 6 months, there was also a net benefit of aclidi-
nium on RS-Total score in both Groups A + C and B +
D, taking into account both those who respondedcompared with no change, and no change compared
with those who deteriorated. Taken together, these
results suggest aclidinium improves daily respiratory
symptoms, regardless of symptom severity at baseline,
although results for the RS-Cough & Sputum domain
for GOLD Group A + C need to be interpreted with cau-
tion because of the imbalance between treatment groups
at baseline. In GOLD Groups A and C, the domain in
which most patients scored highest was Cough & Spu-
tum, suggesting that this may represent the major cause
of respiratory symptoms in these patients. However, it
should be noted that there may be a bias introduced
here by the method of patient attribution to GOLD
group. Whilst the SGRQ does have items concerning
cough and sputum, more of them are related to breath-
lessness and activity, therefore people diagnosed with
COPD who have low SGRQ scores are likely to have
some respiratory symptoms (otherwise they may not
have been diagnosed) and a higher level of cough and
sputum may be more apparent in that subgroup.
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Fig. 1 Distribution of E-RS scores at baseline, overall and by pooled GOLD group. n = patients with available data. a RS Total score, ranged 0 to 40.
b RS-Breathlessness domain score, range 0 to 17. c RS-Cough & Sputum domain score, range 0 to 11. d RS-Chest Symptoms domain score, range
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validity of E-RS scores. A strong association was seen
between E-RS Total score responder status and SGRQ
total responder status. Most patients with symptomatic
improvement also experienced improvements in health
status, although further study of E-RS responders who
did not experience meaningful improvements in health
status and E-RS non-responders who reported improve-
ments in health status is warranted.
These data also offer insight into the symptomatic mani-
festations of GOLD Groups A–D when health status is the
grouping criterion. RS-Total and domain scores were
higher in patients with poorer health status (Group B +D),
indicating that these patients had more severe respiratorysymptoms, including breathlessness, cough and sputum,
and chest symptoms, although this does not necessarily
mean that all of these patients experienced severe symp-
toms, or that those with better health status (Group A +C)
were symptom free. Approximately 20–30 % of patients in
GOLD Group B +D had an RS-Total score ≤10, and
13–17 % of those in Group A +C had an RS-Total score
≥10. Previous studies have shown that, whilst there is a
good degree of concordance between patients categorized
into GOLD groups based on breathlessness (mMRC score
≥1) or health status (CAT score ≥10), the distribution of
patients is not identical [15, 16]. The results reported here
are consistent with these studies and also suggest that
groupings based on the cardinal symptoms of COPD (i.e.
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Fig. 2 Change from baseline in E-RS scores and proportion of E-RS responders at Week 24, overall and by GOLD group a and b RS-Total score;
c and d RS-Breathlessness domain; e and f RS-Cough & Sputum domain; g and h RS-Chest Symptoms domain. *p < 0.05, **p < 0.01, ***p < 0.001
vs placebo. Change from baseline data are LS means (SE). Responder data are OR (95 % CI). aplacebo n = 578; aclidinium n = 583; bplacebo n = 72;
aclidinium n = 64; cplacebo n = 506; aclidinium n = 519. BID, twice daily; CI, confidence interval; E-RS, Evaluating Respiratory Symptoms; GOLD,
Global initiative for chronic Obstructive Lung Disease; LS, least squares; OR, odds ratio; SE, standard error
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may be more effective than either dyspnea alone or the
broader construct of health status. It is also important to
note that the E-RS thresholds used here to designate ‘high’
or ‘low’ symptoms were exploratory and were based on
historical score distributions, with further study warranted.0
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demonstrated that E-RS scores were significantly corre-
lated with other clinical outcomes, including health status,
relief-medication use and alternate measures of symptom
severity [11]. The strongest correlations were between
baseline E-RS scores and SGRQ total score, consistent
with several previous studies that have also shown an as-
sociation between COPD symptoms and health status
[16–18]. In contrast, the relationship between FEV1 and
respiratory symptoms was weak, consistent with previous
research, including a recent observational study which
demonstrated that, in patients in clinical practice, the
presence of respiratory symptoms was similar in patients
across all severities of airflow obstruction [18]. Together,
these results highlight the importance of broad assessment
of patients’ FEV1 and symptoms, consistent with the
GOLD strategy document [1].
Conclusions
In this pooled post-hoc analysis of two randomized
controlled trials, E-RS scores detected statistically significant
and meaningful improvements in daily respiratory symp-
toms with aclidinium 400 μg BID compared with placebo in
patients with moderate to severe COPD. This benefit
appears to be irrespective of symptom severity at baseline.
Total and domain scores also provided interesting insight
into the symptomatic manifestations of GOLD Groups
A–D. Results support the use of the E-RS: COPD as a mea-
sure of respiratory symptoms in clinical trials of COPD.
Endnotes
1The EXACT™ and E-RS™ are owned by Evidera. Permis-
sion to use these instruments may be obtained from Evidera
(exactpro@evidera.com).
2Registered trademark of AstraZeneca group of compa-
nies; for use within the USA as Pressair®; and as Genuair™
within all other licensed territories.
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